Serial Number 98259188
Registration 7594801
700

Registration Progress

Application Filed
Nov 7, 2023
Under Examination
Approved for Publication
Oct 8, 2024
Published for Opposition
Oct 8, 2024
Registered
Dec 10, 2024

Trademark Image

Basic Information

Serial Number
98259188
Registration Number
7594801
Filing Date
November 7, 2023
Registration Date
December 10, 2024
Published for Opposition
October 8, 2024
Drawing Code
2

Status Summary

Current Status
Active
Status Code
700
Status Date
Dec 10, 2024
Registration
Registered
Classes
005

Rights Holder

Takeda Pharmaceuticals International AG

99
Address
Thurgauerstrasse 130
Glattpark-Opfikon 8152
CH

Ownership History

Takeda Pharmaceuticals International AG

Original Applicant
99
Glattpark-Opfikon CH

Takeda Pharmaceuticals International AG

Owner at Publication
99
Glattpark-Opfikon CH

Takeda Pharmaceuticals International AG

Original Registrant
99
Glattpark-Opfikon CH

Legal Representation

Attorney
Karl M. Zielaznicki, Esq.

USPTO Deadlines

Next Deadline
1961 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-12-10)
Due Date
December 10, 2030
Grace Period Ends
June 10, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

25 events
Date Code Type Description Documents
Dec 10, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Dec 10, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Oct 8, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 8, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Sep 18, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 30, 2024 ALIE A ASSIGNED TO LIE Loading...
Aug 30, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 30, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 30, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 29, 2024 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Mar 27, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Mar 27, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Mar 27, 2024 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Mar 27, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Mar 27, 2024 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Mar 27, 2024 CNSL R SUSPENSION LETTER WRITTEN Loading...
Mar 27, 2024 GNSL F LETTER OF SUSPENSION E-MAILED Loading...
Mar 24, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Mar 24, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Mar 24, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Mar 24, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Mar 20, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Dec 7, 2023 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Dec 6, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 10, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of neurological diseases

Additional Information

Design Mark
The mark consists of a solid orange circle surrounded by a broken yellow circle design, which is interrupted by a green circle with an open center on the top left side. The white in the drawing, including in the center of the green circle, represents background and is not part of the mark.
Color Claim
The color(s) green, yellow, and orange is/are claimed as a feature of the mark.

Classification

International Classes
005